Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
B-57The Temporal Onset of Cognitive Fatigue in Multiple Sclerosis.
The Brd4 acetyllysine-binding protein is involved in activation of polyomavirus JC.
In situ expansion of T cells that recognize distinct self-antigens sustains autoimmunity in the CNS.
Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease.
Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: Comparison with Memantine.
Dimethyl fumarate (Tecfidera) for multiple sclerosis.
Endocannabinoids and neurodegenerative diseases.
A cross-sectional study examining multiple mobility device use and fall status among middle-aged and older adults with multiple sclerosis.
Extracranial Venous Drainage Patterns in Patients with Multiple Sclerosis and Healthy Controls.
Serum level of interleukin-6 in Chinese patients with multiple sclerosis.
Non-lesional white matter changes in pediatric multiple sclerosis and monophasic demyelinating disorders.
Placebo power.
Immune modulating peptides for the treatment and suppression of multiple sclerosis.
The next generation of exoskeletons: lighter, cheaper devices are in the works.
A touch of MS: Therapeutic mislabeling.
Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
Removing confounding factors via constraint-based clustering: An application to finding homogeneous groups of multiple sclerosis patients.
▼Dimethyl fumarate for relapsing-remitting multiple sclerosis.
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Relapses in patients treated with fingolimod after previous exposure to natalizumab.
Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study.
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Diagnostic Ability of a Linear Discriminant Function for Spectral-Domain Optical Coherence Tomography in Patients with Multiple Sclerosis.
Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.

Pages